Evidence map›Paper›PMID 35306035›Full record

Observational studyAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2022

Estimated GFR Slope Across CKD Stages in Primary Hyperoxaluria Type 1.

Prince Singh, Lisa E Vaughan, Phillip J Schulte, David J Sas, Dawn S Milliner, John C Lieske

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Trial
  2. Article
  3. Urine Oxalate Excretion and CKD Stage in Patients With Primary Hyperoxaluria Type 1.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2026
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Prince SinghDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Lisa E VaughanDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota.
Phillip J SchulteDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota.
David J SasDivision of Pediatric Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Dawn S MillinerDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; Division of Pediatric Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
John C LieskeDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. Electronic address: lieske.john@mayo.edu.
Mayo Clinic · US

Funding

Primary HyperoxaluriaU54DK083908 · NIDDK · MAYO CLINIC ROCHESTER · PI MILLINER, DAWN SCHMAUTZ · 2009 to 2018
$12.3M
VISUALIZATION AND PATHOPHYSIOLOGY OF RENAL STONE PRECURSOR LESIONSU54DK100227 · NIDDK · MAYO CLINIC ROCHESTER · PI LIESKE, JOHN C · 2013 to 2017
$6.3M
Facilitating personalized medicine of monogenic stone patients by genetic characterizationR21TR003174 · NCATS · MAYO CLINIC ROCHESTER · PI HARRIS, PETER C., LIESKE, JOHN C · 2020 to 2021
$437k
NCATS NIH HHS R21 TR003174NIDDK NIH HHS U54 DK083908NIDDK NIH HHS U54 DK100227
6 · The paper itself

Abstract

RATIONALE &

objectivePrimary hyperoxaluria type 1 (PH1) is an autosomal recessive disorder of glyoxylate metabolism that results in early-onset kidney stone disease, nephrocalcinosis, and kidney failure. There is an unmet need for reliable markers of disease progression to test effectiveness of new treatments for patients with PH. In this study, we assessed the rate of estimated glomerular filtration rate (eGFR) decline across chronic kidney disease (CKD) glomerular filtration rate (GFR) categories (CKD G2-G5) in a cohort of patients with PH1. STUDY

designRetrospective observational study. SETTING &

participantsPatients with PH1 enrolled in the Rare Kidney Stone Consortium (RKSC) registry who did not have kidney failure at diagnosis and who had at least 2 eGFR values recorded from within 1 month of diagnosis until their last contact date or incident kidney failure event. PREDICTORS: CKD GFR category, baseline patient and laboratory characteristics. OUTCOME: Annualized rate of eGFR decline. ANALYTICAL APPROACH: Generalized estimating equations and linear regression were used to evaluate the associations between CKD GFR category, baseline patient and laboratory characteristics, and annual change in eGFR during follow-up.

resultsCompared with the slope in CKD G2 (-2.3 mL/min/1.73 m LIMITATIONS: Data at regular time points were not available for all patients due to reliance on voluntary reporting in a retrospective rare disease registry.

conclusionsThe eGFR decline was not uniform across CKD GFR categories in this PH1 population, with a higher rate of eGFR decline in CKD G3b and G4. Thus, CKD GFR category needs to be accounted for when analyzing eGFR change in the setting of PH1.

Indexed as

Kidney CalculiRenal Insufficiency, ChronicDisease ProgressionGlomerular Filtration RateHumansHyperoxaluria, PrimaryRetrospective StudiesChronic kidney disease (CKD)CKD progressioneGFR slopeeGFR trajectoryestimated glomerular filtration rate (eGFR)kidney failurekidney stonenephrocalcinosisPH1plasma oxalateprimary hyperoxaluria (PH)renal functionsurrogate end pointurinary oxalate

Identifiers

PMID35306035
PMCPMC9398980
OpenAlexW4220702101

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.